arrow
A

Arijs, Ingrid

KU Leuven
H指数:0
被引数:48

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Willingness to switch from optimized intravenous to subcutaneous infliximab in IBD: baseline characteristics from the AMARETTO trial

从优化静脉用英夫利昔转换为皮下注射英夫利昔在炎症性肠病中的意愿:AMARETTO试验的基线特征

2026-01-010
PRE
Single-cell mapping of alternative splicing linked to checkpoint immunotherapy response

单细胞图谱分析:与免疫检查点疗法反应相关的选择性剪接

2025-11-260
PRE
P1008 Subcutaneous infliximab in IBD patients previously treated with an optimized intravenous infliximab dosing schedule: preliminary results on expectations and satisfaction of switching from intravenous to subcutaneous infliximab
2025-01-220
PRE
PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma
2023-11-2911
OAAI
A Core Outcome Set for Inflammatory Bowel Diseases: Development and Recommendations for Implementation in Clinical Practice Through an International Multi-stakeholder Consensus Process
2023-11-294
OAAI
Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers
2023-08-2410
OA
Analysis of cell free DNA to predict outcome to Bevacizumab combination therapy in metastatic colorectal cancer patients
2023-04-040
OA
Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity
2021-07-05162
OAAI
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities

全基因组测序揭示了进行性和稳定的骨髓瘤前体疾病是两个不同的实体

2021-03-2578
OAAI
Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies
2020-07-0864
OAAI